Our results demonstrate significant efficacy of the novel rexinoid V-125 for prevention and treatment in the MMTV-Neu model of HER2 + breast cancer and prevention in the A/J model of Kras-driven NSCLC. This evidence concerns the gene KRAS and breast carcinoma.